ApoGlyx
PrivateLast Round
VC Round
Oct 25, 2021
Total Funding Raised
$605,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ApoGlyx is a biotechnology company developing first-in-class therapies based on aquaporin inhibitors for inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ApoGlyx Comparables
Compare ApoGlyx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrivo BioVentures | 80% | |
| Lamassu BioTech | 78% | |
| CalciMedica Inc. | 73% | |
ApoGlyx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Oct 25, 2021 | ||||
| Seed | Jun 2, 2016 |
ApoGlyx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LU Innovation | Seed |
| Almi Invest AB | VC Round |
| SmiLe Venture Hub | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 18, 2026
Monthly visitors grew 48% MoM, reaching 1K.
- Oct 25, 2021
$678K round led by Almi Invest
ApoGlyx Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ApoGlyx's valuation, stock price, and market status.